Novo Nordisk Pob shares by 5 % after wegovy received approval for liver disease

The Novo Nordisk shares increased about 5 % on Monday after the company received a accelerated approval from the US Food and Drug Administration to treat a serious liver disease.

The company said on Friday that it has been granted approval to treat sebaceous hepatitis associated with metabolism (MASH) in adults with moderate to the applicant, in conjunction with a low -calorie diet and increased physical activity.

Novo Nordisk shares increased by 5.32 % by 10:20 am London time (5:20 am East time).

Approval makes Wegovy the first GLP-1 category to be declared by Mash, a progressive liver condition that affects an estimated 5 % of American adults, according to the American Liver Foundation.

It also advances in drug applications that go beyond diabetes treatment and obesity and the development of its presence in the metabolic diseases market. Approval follow a series of studies that indicate Drug effectiveness In reducing the risk of heart attack, stroke and death, the causes of the heart and blood vessels.

Martin Holst Lang, Executive Vice President of Scientific Science and Scientific Officer in the statement, said in a statement: “Wegov is now in a unique position as the first and only GLP-1 treatment for mash, and it has completed the already installed weight loss, cardiovascular benefits, and a wide range of evidence associated with arglotide,” said Martin Holst Lang, Executive Vice President of Scientific Science and Scientific Officer in the statement in a statement.

The accelerating approval was based on the first stage of the Essence experience, in which Novo Nordisk Wegov said It showed “an important and superior improvement” in cirrhosis compared to imaginary therapy.

Under the study, the company said that nearly two -thirds of (62.9 %) of people treated with Wegov achieved a solution of fatty hepatitis without exacerbation of liver fibrosis, compared to 34.3 % who received an imaginary drug.

More than a third (36.8 %) of those treated with Wegov achieved an improvement in liver fibrosis with no exacerbation of fatty hepatitis after 72 weeks, compared to 22.4 % who received an imaginary drug.

This is a developing story. Please check again for updates.